{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpce.simplecast.com%2Fepisodes%2Fcdk4-6i-in-hr-her2-bc-VKfua4oX","width":444,"version":"1.0","type":"rich","title":"Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/bfa3b13b-ef5e-4a6d-bf6e-9d3eb8b27084/pod462-oncology-spring-conferences-podcast-hr-her2.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/27dde2f1-363f-47d1-b16e-86abe72cc4a9\" height=\"200\" width=\"100%\" title=\"Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast, an advanced practice provider discusses the latest guidance on integrating CDK4/6 inhibitors into treatment of early-stage and metastatic HR+/HER2- breast cancer. Cases from her practice illustrate how to approach treatment selection and manage important adverse events."}